ArticleInfectious agents and cancer2025
Prevalence and genotype distribution of HPV infection among women in Chengdu from 2019 to 2024: a retrospective single-center study.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- An epidemiological survey of HPV infection among women in Southern Hebei, China.Virology journal · 2026Article
- Urban-rural disparities in HPV prevalence and genotype distribution: a large-scale cervical cancer screening study in Xi'an, China.BMC infectious diseases · 2026Article
- Epidemiological analysis of sexually transmitted infections pathogens and related microorganisms in South Korea: coinfection patterns and pathogen correlations.BMC infectious diseases · 2026Article
- Utility of extended HPV genotyping in cervical cancer screening: a prospective population-based cohort study in China.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHuman papillomavirus (HPV) infection is closely associated with the occurrence and development of cervical cancer. This study comprehensively investigates HPV infection and subtype distribution among women in Chengdu from 2019 to 2024, aiming to provide scientific evidence for screening, prevention, and optimization of HPV vaccination strategies against cervical cancer and related diseases.
methodsCervical exfoliated cell specimens from 65,130 female patients attended Sichuan Jinxin Xinan Women & Children Hospital from 2019 to 2024 were collected and detected 26 HPV gene subtypes using gene chip technology.
resultsAmong the 65,130 women included in the study, 13,463 were HPV positive, with an overall detection rate of 20.67%. The single infection rate was 14.80%, and the multiple infection rate was 5.88%; the infection rates for pure HR-HPV, pure LR-HPV, and mixed infections were 13.86%, 3.90%, and 2.92%, respectively. The HPV detection rate was highest in those aged ≤ 20 years (46.01%) and among those aged > 60 years (35.37%), showing a bimodal distribution across ages. The top five HR-HPV subtypes detected were HPV52, 58, 16, 51, and 39, with infection rates of 3.71%, 2.81%, 2.56%, 1.83%, and 1.64%, respectively. The top three LR-HPV subtypes were HPV54, 42, and 40, with detection rates of 1.85%, 0.99%, and 0.93%, respectively. From 2019 to 2024, HPV detection showed a U-shaped trend, with a significant decrease in HPV16 detection rate and an increase in HPV42. Among other subtypes co-infected with the top five HR-HPV subtypes, HPV52 and HPV58 accounted for the highest proportion. After 2023, co-infections with LR-HPV increased.
conclusionDuring 2019-2024, the HPV infection rate among women in Chengdu was high with an increase in detection rates after 2023. The co-infection patterns of HR-HPV are complex. Infection rates are highest among women aged ≤ 20 years and > 60 years. Priority should be given to young women for vaccination. HPV screening should be strengthened for women across different age groups. Developing vaccines targeting locally prevalent HPV subtypes is crucial for reducing infection rates and preventing cervical cancer and other HPV-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.